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Purpose: The aim of this retrospective cohort study was to assess treatment outcome, and acute pulmonary and
esophageal toxicity using intensity modulated (sequential/concurrent chemo)radiotherapy (IMRT) in locally
advanced stage III non-small cell lung cancer (NSCLC).
Methods and materials: Eighty-six patients with advanced stage NSCLC, treated with either IMRT only (66 Gy) or
combined with (sequential or concurrent) chemotherapy were retrospectively included in this study. Overall survival
and metastasis-free survival were assessed as well as acute pulmonary and esophageal toxicity using the RTOG
Acute Radiation Morbidity Scoring Criteria.
Results: Irrespective of the treatment modality, the overall survival rate for patients receiving 66 Gy was 71%
(±11%; 95% CI) after one year and 56% (±14%) after two years resulting in a median overall survival of 29.7 months.
Metastasis-free survival was 73% (±11%) after both one and two years. There were no statistically significant
differences between the treatment groups. Treatment related esophageal toxicity was significantly more
pronounced in the concurrent chemoradiotherapy group (p = 0.013) with no differences in pulmonary toxicity.
Conclusions: This retrospective cohort study in advanced non-small cell lung cancer patients shows that IMRT is an
effective technique with acceptable acute toxicity, also when (sequentially or concomitantly) combined with
chemotherapy.
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Lung cancer is an increasing cause of death in devel-
oping and developed countries, accounting for 1.39
million deaths worldwide in 2008. Non-small cell
lung cancer (NSCLC) accounts for approximately
85% of all lung cancer cases [1]. The treatment of
choice for individuals with local NSCLC, stage I, II
and IIIA (T3N1), is surgical resection. Based on large
series of resected stage I and II NSCLC, five-year
survival rates are commonly reported to be 60 to
80% and 40 to 50%, respectively [2]. In patients with
locally advanced NSCLC, stage IIIA (N2) and IIIB,* Correspondence: j.bussink@rther.umcn.nl
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reproduction in any medium, provided the orconcurrent radiochemotherapy is recommended [3,4].
However, survival rates with these approaches are
only in the order of 15%, and a lot of patients are
not eligible to undergo this intensified regimen [5,6].
Considering the fact that treatment failure most
often occurs at the primary tumor site, improvement
in overall survival of locally advanced stage III
NSCLC can be achieved through better local control.
A meta-analysis by Aupérin et al. proved concurrent
regimens to be superior to sequential ones in terms
of locoregional control and overall survival [5]. In
concurrent schedules, the chemotherapeutic agents
enhance the tumor’s radiosensitivity and thus the
local treatment efficacy, but this comes at the cost of
increased toxicity.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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therapy, another approach to accomplish better locore-
gional control is dose escalation. Several studies have
shown that this strategy improves local control and
consequently overall survival of locally advanced stage
III NSCLC [7-11]. Using three-dimensional conformal
radiation therapy (3D-CRT) allows dose escalation
without excessive toxicity, while improving overall sur-
vival rates [12,13]. Compared with 3D-CRT, intensity-
modulated radiation therapy (IMRT) enables even tigh-
ter sculpting of high-dose regions around the tumor
volume, creates steep dose gradients and thus reduces
radiation dose to surrounding normal tissues, ultim-
ately facilitating dose-escalation [14]. Therefore, the
University of Texas M.D. Anderson Cancer Center
investigated the rate of high-grade treatment-related
pneumonitis in patients with advanced NSCLC treated
with concurrent chemotherapy and IMRT. Toxicity
rates were compared with a similar cohort of patients
treated with 3D-CRT (median radiation dose 63 Gy for
both treatment modalities). The levels of Grade ≥3 ra-
diation pneumonitis at 12 months according to RTOG
toxicity scoring [15] were significantly (p = 0.002) lower
for IMRT than for 3D-CRT, being 8% (95% CI 4%–19%)
and 32% (95% CI 26%–40%), respectively [16]. This ini-
tial evaluation is consistent with the conclusion of a
subsequent study of the institution in larger patient
groups and with longer follow-up times [17]. Of the
496 NSCLC patients, 318 were treated with CT/3D-
CRT and 91 with 4DCT/IMRT. The hazard ratio for
4DCT/IMRT was 0.33 (95% CI 0.13-0.82; p = 0.017) for
Grade ≥3 radiation pneumonitis, indicating lower tox-
icity rates were associated with 4DCT/IMRT. These
findings were confirmed by other studies [14,18]. Fur-
thermore, IMRT reduces radiation doses to the esopha-
gus, heart and spinal cord [18,19].
Published clinical data on outcome and toxicity using
IMRT in stage III NSCLC are scarce. Therefore, the
aim of the present retrospective cohort study was to
evaluate outcome, and acute pulmonary and esophageal
toxicity using intensity modulated (sequential/concur-




All patients with advanced-stage irresectable NSCLC
treated with curative intent at our institution between
March 2008 and February 2011, eighty-six in total,
were retrospectively included in this study. All re-
search was carried out in compliance with the Helsinki
Declaration and in accordance with Dutch law. The
Institutional Review Board waved review due to the
retrospective nature of this study. All primary tumorsand the mediastinal N2 disease were cytologically or
histologically proven. Prior to treatment initiation,
patients underwent total body 18F-fluorodeoxyglucose
positron emission tomography combined with low
dose computed tomography (FDG PET-CT) and MRI
scan of the brain for tumor staging purposes. Patients
in good general condition were treated with concur-
rent chemoradiotherapy, those with a contraindication
for chemotherapy were treated by radiation alone, and
all remaining patients were treated with a sequential
chemotherapy and radiotherapy. The planned radi-
ation dose to the primary tumor and metastatic medi-
astinal lymph nodes using IMRT was 66 Gy in 33
fractions delivered five times per week. Chemothera-
peutic agents in the sequential regimen typically con-
sisted of three courses of gemcitabine (1250 mg/m2;
on day 1 and 8) and cisplatinum (80 mg/m2; on day 1).
The concurrent schedules varied between referring
hospitals; in Radboud University Nijmegen Medical
Centre it consisted of two courses of etoposide
(100 mg/m2; on day 1–3) and cisplatinum (50 mg/m2;
on day 1 and 8), in Canisius-Wilhelmina Hospital one
course of gemcitabine/cisplatinum was administered
prior to irradiation and two courses of etoposide/cis-
platinum concurrently with radiation therapy.
Organ segmentation and treatment planning technique
The gross tumor volume (GTV) encompassed the primary
tumor volume defined on a contrast-enhanced slow-CT
scan and the positive mediastinal lymph nodes as defined
on CT imaging (short axis > 1 cm or necrosis). Besides, it
included cytologically or histopathologically confirmed
pathological FDG-avid lesions. Subsequently, the planning
target volume (PTV) was created following the institute’s
guidelines. Automatic contouring of the lungs and heart
was performed using the Pinnacle3 treatment planning
system (version 8.0 h; Philips Radiation Oncology Sys-
tems, Fitchburg, USA). Manual correction was performed
if necessary. The esophagus was delineated from the lower
border of the cricoid cartilage to the gastro-esophageal
junction. The spinal cord was considered to be at the
inner margin of the entire bony thoracic spinal canal.
An IMRT treatment plan was generated using a 3D
convolution/superposition method for dose calcula-
tion, and a standard radiation beam geometry not
encompassing the healthy contralateral lung. Multi-
segment fields were generated for IMRT delivery on a
step-and-shoot linear accelerator (Elekta SLi; Elekta
AB, Stockholm, Sweden) using six co-planar 10 MV
photon beams. Plans had been limited to 60 segments
with a minimum segment area of 6 cm2 and at least 10
monitor units. Treatment plans had been optimized
using an in-house developed class solution for inverse
treatment planning with the direct machine parameter
Table 1 Patient characteristics (n = 86); TNM classification
according to 7th edition of International Association for
the Study of Lung Cancer
Age (y)
median [range] 67.2 [44.6; 82.7]
Morphology (n)
squamous cell carcinoma 33
adenocarcinoma 34
neuroendocrine carcinoma 1
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segments. All plans had been normalized to a mean
dose of 66 Gy in 33 fractions and satisfied the −5% and
+7% dose heterogeneity criteria for the PTV according
to ICRU 50/62 guidelines [20,21]. Routinely, position
verification was performed using EPID or, from 2009
onwards, MV conebeam-CT imaging with an offline
(NAL; no action level [22]) protocol (fraction 1, 2, 3


















concurrent RT and CHT 37
sequential RT en CHT 42Assessment of pulmonary and esophageal toxicity
During the course of radiation delivery, patient toxicity
was weekly assessed by the treating physician accord-
ing to the RTOG acute toxicity scoring criteria [15].
Pulmonary and esophageal toxicities were scored on a
6-point scale. For pulmonary toxicity grade 0 was
defined as absence of symptoms, grade 1 as mild dry
cough or dyspnea on exertion, grade 2 as persistent
cough requiring narcotic antitussive agents, grade 3 as
severe cough unresponsive to narcotic antitussive
agent requiring steroids and intermittent oxygen, and
grade 4 as severe respiratory insufficiency requiring
continuous oxygen or assisted ventilation. For esopha-
geal toxicity, grade 0 was defined as absence of symp-
toms, grade 1 as slight symptoms requiring no or non-
narcotic analgesics, grade 2 as symptoms requiring
narcotic analgesics and adapted diet, grade 3 as severe
dysphagia with dehydration or weight loss requiring
nasogastric tube feeding of intravenous fluids, and
grade 4 complete obstruction, ulceration, perforation
or fistula. For both toxicities grade 5 was considered
toxicity related death.RT alone 7
n = number of patients, y = years, RT = radiotherapy; CHT = chemotherapy.Statistical analysis
We retrospectively reviewed the records of the patients
in the cohort until March 31, 2011. Clinical end points
were overall survival and metastasis-free survival.
Metastasis-free survival was based on clinical basis
and, if metastases were suspected, adequate imaging
was performed, e.g., liver ultrasound, CT of thorax/ab-
domen, FDG-PET or bone-scan. These clinical end
points with respect to the different treatment groups
were calculated using the Kaplan-Meier method
(GraphPad Prism, version 4.0, GraphPad Software,
La Jolla, USA). Due to the retrospective nature of this
study including patients from several referring hospitals,
no reliable data on local and regional control were available
and thus not analyzed. For comparison of pulmonary and
esophageal toxicity between the different treatment sche-
dules, the chi-square test was used. A p-value below 0.05
indicated statistical significance and was assessed using
Log Rank test.Results
Patients
The characteristics of the 86 patients are presented in
Table 1. Median age was 67 years, ranging from 45 to
83 years. Three patients with stage IIB (of whom one
was treated for a recurrent disease), 53 with stage IIIA
and 30 patients with stage IIIB were included in the
study. Seven patients were treated with radiotherapy
alone, 42 with sequential chemoradiotherapy, and 37
with concurrent chemoradiotherapy. Three of the 42
patients who received sequential chemotherapy and
radiotherapy did not complete the planned three courses
of chemotherapy due to malaise, a gastrointestinal bleed-
ing and an exacerbation of pancreatitis. Eighty-one per-
cent of the patients was treated with a radiation
prescription dose of 66 Gy, one patient received 67.5 Gy
in 2.25 Gy fractions (stage IIB patient) and 15 received
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opment of metastatic disease during the course of treat-
ment. As a consequence the median irradiated dose was
66 Gy with a range from 32 to 67.5 Gy. Median follow-up
for all patients was 12 months (range, 1–35 months), and
for patients still alive at study closure date it was
17 months (range, 5–39 months).
Treatment outcome
The median overall survival among the 70 patients re-
ceiving a radiation dose of 66 Gy was 29.7 months
(Figure 1). The follow-up of patients treated with radio-
therapy alone and concurrent chemoradiotherapy was
too short to enable the calculation of the median overall
survival time. In patients treated with sequential chemo-
therapy and radiotherapy the median overall survival
was 29.7 months. Irrespective of the treatment modality,
this resulted in an overall survival rate of 71% (±11%;
95% CI) after one year and 56% (±14%) after two years
for patients receiving 66 Gy. In patients treated with ra-
diation only, 1- and 2-year overall survival rates were
80% (55-100%) and 60% (18-100%), respectively. In
patients treated by sequential chemotherapy and radio-
therapy 1- and 2-year overall survival rates were 66%
(±17%) and 55% (±20%), and in patients treated with
concurrent chemoradiotherapy 74% (±16%) and 56%
(±22%), respectively. No statistically significant differ-
ences in overall survival between the treatment groups
were observed.
The median metastasis-free survival of patients re-
ceiving a radiation dose of 66 Gy was not reached in
any of the treatment schedules, and after 1 and 2 years,
the metastasis-free survival rates were both 73%
(±13%) (Figure 2). Among patients receiving a radi-
ation dose of 66 Gy without additional chemotherapy,Figure 1 Kaplan-Meier estimate of overall survival in patients receivin
concurrent chemotherapy.the 1- and 2-year metastasis-free survival rates were
both 75% (33-100%). Among patients treated with se-
quential chemotherapy and 66 Gy of radiotherapy, the
rates were 73% (±16%) and 66% (±20%) at 1 and
2 years, respectively. In patients concurrently treated
with chemoradiotherapy, the metastasis-free survival
was 73% (±16%) at both time-points. No statistically
significant difference between the treatment groups
was observed. Most commonly, distant metastases
occurred simultaneously at multiple sites (5 patients)
or separately in bone (8 patients), brain (5 patients) or
liver (3 patients).
Acute pulmonary and esophageal toxicity
Table 2 summarizes the acute treatment-related pul-
monary and esophageal toxicity of the patients. Of all
patients, 13 (15%) experienced no acute pulmonary
toxicity, 51 (60%) mild dry cough or dyspnea on exer-
tion, and 20 (23%) grade 2 symptoms. Pulmonary tox-
icity did not statistically differ between treatment
schedules. No acute esophageal toxicity was observed
in 12 patients (13%), slight symptoms requiring no or
non-narcotic analgesics in 43 (50%) and esophageal
toxicity requiring narcotic analgesics and adapted diet
in 30 patients (35%). Thereby, esophageal toxicity
differed statistically significant between patients under-
going sequential or concurrent chemoradiotherapy,
unfavorable for the latter (p = 0.013). Neither grade 3
nor grade 4 pulmonary or esophageal toxicity was
observed and no patient died of treatment-related
causes.
Discussion
The number of clinical studies evaluating treatment out-
come on the use of IMRT for locally advanced NSCLC isg a radiation dose of 66 Gy only, or combined with sequential or
Figure 2 Kaplan-Meier estimate of metastasis-free survival in patients receiving a radiation dose of 66 Gy only, or combined with
sequential or concurrent chemotherapy.
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use of IMRT in patients with irresectable NSCLC. We
found among all patients receiving 66 Gy 1- and 2-year
overall survival rates of 71% and 56%, respectively, and a
median overall survival of 29.7 months.
Several studies have addressed treatment outcome
using 3D-CRT or IMRT for advanced stage NSCLC
patients. Nakayama et al. compared the clinical results
of high dose 3D-CRT (66 to 84 Gy) with those of con-
ventional two-dimensional radiotherapy (56 to 66 Gy)
for patients with Stage III NSCLC [13]. The overall sur-
vival rates at 3 years were 9.1% (95% CI, 0.7–18.9%) in
the conventional group and 31.0% (95% CI, 18.9–
43.1%) in the high-dose group. Wang et al. retrospect-
ively evaluated the outcome of 237 stage III NSCLC
patients treated with radiotherapy alone, sequential
chemoradiotherapy or concurrent chemoradiotherapy
using 3D-CRT [9]. The median overall survival of the
entire cohort was 12.6 months, and 2- and 5-year over-
all survival rates were 22.4% and 10.0%, respectively.
Recently, the Memorial Sloan-Kettering Cancer CenterTable 2 Frequency (and % of patients in the respective
treatment group) of acute pulmonary and esophageal
toxicity in patients according to treatment
Pulmonary toxicity Esophageal toxicity
Treatment Grade 0 Grade 1 Grade 2 Grade 0 Grade 1 Grade 2
RT$ 0 (0) 4 (57) 3 (43) 2 (29) 3 (43) 2 (29)
CHT-RT# 4 (10) 26 (62) 10 (24) 8 (19) 24 (57) 9 (21)
RCHT 9 (24) 21 (57) 7 (19) 2 (5) 16 (43)* 19 (51)*
$RT = radiotherapy alone; #CHT-RT = sequential chemotherapy and
radiotherapy; }RCHT = concurrent chemoradiotherapy. * p = 0.013; chi-square
test of sequential versus concurrent chemoradiotherapy. For the sequential
chemotherapy and radiotherapy group, numbers on acute pulmonary and
esophageal toxicity are missing for 2 patients and 1 patient, respectively.retrospectively reviewed treatment outcome of 55 stage
I-IIIB inoperable NSCLC patients with large tumor
volumes (GTV ≥ 100 cc) treated with IMRT [23]. For
patients with stage III disease, 2-year local control and
overall survival rates were both 58%, respectively, with a
median survival time of 25 months. Liao et al. reviewed
the records of 91 patients who received treatment with
concurrent chemoradiotherapy using 4DCT/IMRT and
compared outcome with patients treated with CT/3D-CRT
[17]. The hazard ratio for 4DCT/IMRT was 0.64 (95% CI
0.41-0.98) and statistically significant (p = 0.039) for the
overall survival. Based on these reports on 3D-CRT and
IMRT [8,9,13,19], and our observations, we consider IMRT
as an effective treatment option for patients with locally
advanced NSCLC.
Besides favorable outcome data, no severe treatment-
related acute pulmonary or esophageal toxicity was
observed. In line with previous reports, however, acute
esophageal toxicity was enhanced in concurrent sche-
dules compared to sequential chemoradiotherapy [5,6].
Sura et al. scored acute toxicity on the RTOG scale
and reported six patients (11%) to experience grade 3
acute pulmonary toxicity and two (4%) to experience
grade 3 acute esophagitis, with no grade ≥4 acute tox-
icity [23]. Using the CTCAE version 3.0 scoring criteria
[24], Yom et al. reported an incidence of grade ≥3
treatment-related pneumonitis in the IMRT group of
8% (95% CI, 4%–19%) at 6 and 12 months [16].
Differences in treatment outcome and toxicity may be
attributable to different GTV volumes, delivered treat-
ment schedules and radiation dose, tumor stage and
the number of patients included in the study. In our
study, the patient’s performance status was not expli-
citly taken into account. Nevertheless, the treatment
choice is dependent on the performance score and only
patients in good general condition, i.e., Karnofsky index
Govaert et al. Radiation Oncology 2012, 7:150 Page 6 of 7
http://www.ro-journal.com/content/7/1/150≥70%, were considered candidates for concurrent
chemoradiotherapy.
There are some concerns with respect to the use of
IMRT in daily practice. One such concern is the effect
of respiratory motion on the accuracy of IMRT delivery
[25]. However, several studies have shown that dose
variation, introduced by organ motion, almost com-
pletely disappears when delivering fractionated radio-
therapy [26-28]. Furthermore, in our institute a slow-
CT scan is routinely performed for treatment planning
purposes incorporating all tumor motion into the defin-
ition of the GTV. By doing so, the respiratory motion
has largely the same effect on IMRT dose distributions
as on conformal radiotherapy techniques. Another con-
cern of IMRT is low-dose radiation exposure of larger
volumes of unaffected lung tissue. In the era of 3D-
CRT, the mean lung dose (MLD; [29]) and the volume
of unaffected lung tissue receiving a dose of at least
20 Gy (V20) were most often dose-limiting. By applying
highly-conformal techniques such as IMRT, however,
the MLD alone is more often dose limiting than V20.
The reason for this is that by increasing the number of
beams, i.e., adding beams from various angles, a larger
unaffected lung volume is exposed to a low dose of ra-
diation (below 20 Gy, i.e., V20 decreases). Furthermore,
with conformal radiotherapy the PTV is always covered
by all beams at all moments while an intrinsic feature
of IMRT is that with IMRT, the entire PTV is not al-
ways covered by the beam in all its segments. This
allows giving a higher dose to the PTV while V20 is un-
affected, but with a higher MLD. That is explained by a
somewhat higher total dose to the body as a result of
increased monitor units delivered by more radiation
beams [30,31]. As a consequence more radiation-
induced cancers might be expected in long-term survi-
vors [31,32].
Despite these concerns, IMRT outcome results are
very promising and the toxicity rates acceptable, which
supports the consideration of IMRT as an effective and
useful radiotherapy technique for the treatment of lo-
cally advanced NSCLC.
Notwithstanding the encouraging results of IMRT
already reported, more research is needed to further
improve outcome for locally advanced NSCLC. To
improve local control and outcome with modern radio-
therapy techniques in stage III NSCLC patients, a mod-
eling study, investigating the therapeutic gain of
individualized dose prescription with dose escalation
for various hypofractionation schemes, has recently
been conducted at our institution [33]. The encour-
aging findings have resulted in a clinical phase II trial
in which stage III NSCLC patients eligible for (concur-
rent chemo)radiotherapy are treated with individua-
lized escalated dose.Conclusions
This retrospective cohort study in 86 patients with lo-
cally advanced irresectable non-small cell lung cancer
shows that IMRT is an effective technique with accept-
able acute toxicity, also when (sequentially or concomi-
tantly) combined with chemotherapy.
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